Evidence map›Paper›PMID 40940624›Full record

ArticleClinical and experimental nephrology2026

Clinical factors associated with long-term renal outcomes in Japanese patients with IgA nephropathy presenting with nephrotic range proteinuria: a multicenter, retrospective, cohort study.

Tomohiro Saito, Yukihiro Wada, Takanori Shibata, Takashi Yasuda, Yoshinari Yasuda, Keita Hirano, Keiichi Matsuzaki, Tetsuya Kawamura, Yusuke Suzuki, Shoichi Maruyama

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tomohiro Saito *Division of Nephrology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan.
Yukihiro Wada *Department of Nephrology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Takanori ShibataDivision of Nephrology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan. tshibata@med.showa-u.ac.jp.
Takashi YasudaDepartment of Internal Medicine, Kichijoji Asahi Hospital, Tokyo, Japan.
Yoshinari YasudaDepartment of Advanced Science in Renal-Cardio Medicine/Nephrology, Gifu University Graduate School of Medicine, Gifu, Japan.
Keita HiranoDivision of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
Keiichi MatsuzakiDepartment of Public Health, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Tetsuya KawamuraDivision of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
Yusuke SuzukiFaculty of Medicine, Department of Nephrology, Juntendo University, Tokyo, Japan.
Shoichi MaruyamaDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with IgA nephropathy (IgAN) occasionally present with nephrotic range proteinuria (NRP), but the clinical features and long-term renal prognosis of patients with IgAN-related NRP (IgAN-NRP) with or without nephrotic syndrome (NS) remain elusive.

methodsA retrospective, multicenter, cohort study enrolled 788 patients with IgAN from 42 medical centers in 2002-2004. Patients were divided into NRP (group I, n = 39) and non-NRP (group II, n = 749) groups. Group I patients were subdivided into NRP with NS (I-A, n = 14) and NRP without NS (I-B, n = 25) groups. The primary outcome (PO) was a 1.5-fold increase in serum creatinine from baseline. Clinical remission (CR) was defined as both hematuria and proteinuria remission on ≥3 consecutive tests over at least 6 months.

resultsCompared with group II, group I had significantly more severe renal dysfunction and received steroid therapy more frequently. During a median follow-up of 90.0 months, more patients reached the PO in group I (38.5%) than in group II (11.0%). Multivariate analysis of all enrolled patients showed that NRP was a significant independent risk factor for the PO. However, in group I, 10 of 11 patients who achieved CR had a favorable renal prognosis, and corticosteroid therapy significantly attenuated the risk for the PO. When comparing groups I-A and I-B, baseline renal impairment and cumulative probabilities of the PO were comparable.

conclusionRegardless of the presence of NS, IgAN-NRP is a critical factor leading to a poor prognosis, unless CR is achieved. Intensive treatment might be vital for IgAN-NRP.

Indexed as

Glomerulonephritis, IGAKidneyNephrotic SyndromeProteinuriaAdultCreatinineFemaleHematuriaHumansJapanMaleMiddle AgedMultivariate AnalysisPrognosisRemission InductionRetrospective StudiesCreatinineClinical remissionIgA nephropathyNephrotic range proteinuriaNephrotic syndromeRenal prognosis

Identifiers

PMID40940624

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.